SecBot SecBot

ALVO

Alvotech
Nasdaq· Biological Products, (No Diagnostic Substances)· Inc. N4· CIK 0001898416 Biotech & Drug Discovery
$4.62 +0.04 (+0.87%)
Oct 26 4:00 PM ET · prev $4.58
Market cap
$1.9B
Small cap
Consensus
Buy
85% Buy or better · 13 analysts
Median target
$8.00
+73% · range $4.00–9.00
Next earnings
Nov 11
in 15 days
1 year
−43.2%
from $8.13 · Oct 27
30 days
−24.9%
from $6.15
52-week range
$3.00–8.13
−43% from high · low Jun 2
Avg volume 20D
1.04M
Oct 5 spike 2.90M
Short interest
🔒 Subscribers only
New fund stakes
1
Q2 2026 13F · 0 exits
Filing reports
15
analyzed by SecBot
SecBot read BULLISH 9 reports · 90 days
Balance 1 bearish · 7 bullish · 1 neutral oldest → newest, height = score
Avg score ·High conf. 9/9 ·Next Earnings date, Nov 11, 2026
Strongest BULLISH Alvotech and Advanz Pharma announced the first known regulatory submission worldwide for AVT29, a proposed…
All reports →

Price

Daily candles with volume. Pins mark insider trades, rating changes, 13F stakes, reports, catalysts and short-interest jumps.

Signal stack

Where each data set points today.

  • InstitutionsBULLISH

    Q2 2026: 9 added (1 new), 4 trimmed or exited. Largest new: Rubric Capital Management $57.8M.

  • AnalystsBULLISH

    11 of 13 rate it Buy or better. Median target $8.00 (+73%).

  • TrendDOWNTREND

    12% below its 50-day average.

Who's buying

13F· Q2 2026
1
new positions
0
exits
$57.8M
in new stakes
FundMoveSharesValue
Rubric Capital Management LPNEW15,677,093$57.8M
MILLENNIUM MANAGEMENT LLCDOUBLED4,263,644$15.7M
FARALLON CAPITAL MANAGEMENT, L.L.C.DOUBLED2,859,675$10.6M
Legal & General Group PlcADD696,048$2.7M
MORGAN STANLEYDOUBLED670,041$2.5M
STIFEL FINANCIAL CORPADD78,951$291.3K
GOLDMAN SACHS GROUP INCTRIM77,172$284.8K
Quadrature Capital LtdDOUBLED66,599$245.8K

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

13 analysts
Buy 85% rate it Buy or better
Strong Buy4Buy7Hold2Sell0Strong Sell0
12-month targets · 5 analysts

Price is inside the target range. Median implies +73%.Targets as of Oct 27, 2026.

Recent actions
DateFirmActionRating
Sep 16, 2026Barclays
UPGRADE
UPGRADEOverweight
Aug 24, 2026B of A Securities
INITIATE
INITIATEBuy
Aug 14, 2026Evercore ISI Group
INITIATE
INITIATEOutperform

Earnings setup

Estimates
Nov 11
reports in 15 days

Revision history: 🔒 Fresh data, subscribers only

PeriodEPS est.Range30D rev.Revenue
Current Q🔒 Fresh data, subscribers only
Next Q🔒 Fresh data, subscribers only
Current FY🔒 Fresh data, subscribers only
Next FY🔒 Fresh data, subscribers only
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
Upcoming
Nov 11, 2026
Earnings date
ALVO Q3 2026 Earnings Scheduled — 2026-11-11
Recent
Oct 5, 2026
FDA
FDA approves additional U.S. manufacturing capacity for SIMLANDI®, Alvotech’s biosimilar to Humira®
Approval enables AVT02 drug substance for U.S. commercial supply to be manufactured in either of Alvotech’s two Reykjavik drug substance suites
Aug 31, 2026
Announcement
Alvotech announces FDA acceptance for review of Biologics License Application for AVT80, expanding proposed biosimilar program for Entyvio® to subcutaneous presentations
REYKJAVIK, Iceland, August 31, 2026 - Alvotech (NASDAQ: ALVO; ALVO-SDB), a global biotechnology company specializing in the development and…
Aug 27, 2026
Press release
Alvotech to present at upcoming investor conferences in September
REYKJAVIK, ICELAND (August 27, 2026) — Alvotech (NASDAQ: ALVO; ALVO-SDB), a global biotechnology company specializing in the development and…
Aug 21, 2026
Press release
Alvotech Announces Licensing and Commercialization Agreement with Lotus Pharmaceutical for proposed biosimilars to durvalumab and emicizumab in the U.S. and Selected Asian Markets
REYKJAVIK, Iceland, Aug. 21, 2026 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO; ALVO-SDB), a global biotechnology company specializing in the…
Aug 19, 2026
Earnings
Alvotech Announces Financial Results for the First Half of 2026 and Provides a Business Update
REYKJAVIK, ICELAND (August 19, 2026) — Alvotech (NASDAQ: ALVO; ALVO-SDB) (“Alvotech” or the “Company”), a global biotechnology company specializing…

Short side

FINRA· Oct 15, 2026
🔒 Subscribers only
shares short
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Oct 20, 2026 SEC
Alvotech announced FDA approval of a new manufacturing process (Process 2.0) for its Humira biosimilar SIMLANDI…
6-K — Impact 6/10
Oct 14, 2026 SEC
Alvotech and Advanz Pharma announced the first known regulatory submission worldwide for AVT29, a proposed biosimilar…
6-K — Impact 7/10
Oct 7, 2026 SEC
Alvotech announced a long-term strategic manufacturing partnership with LOTTE Biologics, under which LOTTE will…
6-K — Impact 4/10
Oct 5, 2026 Press
FDA approved a supplement to Alvotech's BLA for AVT02 (SIMLANDI®), enabling drug substance manufacturing in a second…
Impact 7/10
Oct 5, 2026 FDA
FDA approves additional U.S. manufacturing capacity for SIMLANDI®, Alvotech’s biosimilar to Humira®
Approval enables AVT02 drug substance for U.S. commercial supply to be manufactured in either of Alv
Jul 3, 2026 Press
Alvotech disclosed that a major shareholder, Celtic Lux Holdings (formerly Alvogen Lux Holdings), has pledged…
Impact 4/10
Jun 30, 2026 Inst.
Rubric Capital Management LP — NEW
15,677,093 shares ($57.8M)
Jun 30, 2026 Inst.
MILLENNIUM MANAGEMENT LLC — DOUBLED
4,263,644 shares ($15.7M)

Washington

New firm · Cgcn New issue · Health IssuesNew issue · Manufacturing Q3 2026 · filed Oct 20
Lobbying Q3 $60K n/a QoQ
YoY n/a vs Q3 2025
Members 0 90 days
Buys / sells 0 / 0 0 trades
HCRHealth IssuesMANManufacturingTARTariff (miscellaneous tariff bills)
8 quarters Open in Washington ›

Corporate Lobbying

This company's lobbying spend, firms, issues and congressional activity are for subscribers.

Subscribe for Full Access

SecBot reports

15 filings · 13 press releases · 8 bullish · 5 bearish · 2 neutral
All ALVO filing & press-release reports (28)